The Cooper Companies, a global medical device titan, operates in two rather intimate corners of human existence: vision and reproduction. Through its CooperVision segment, it meticulously crafts soft contact lenses, ensuring millions can actually see the world, or at least their phone screens, with crystalline clarity. From daily disposables to specialized toric and multifocal lenses, including those designed to manage myopia in children – because even tiny humans deserve to see their future memes clearly – CooperVision offers a comprehensive array of optical solutions. Its competitive edge lies in a premium product mix and recurring demand, a testament to humanity's endless quest for perfect sight and the sheer inconvenience of glasses.

Meanwhile, its CooperSurgical division delves into the profound, and often dramatically expensive, realm of women's health and fertility. Here, the company provides everything from assisted reproductive technology (ART) devices and culture media to contraception, including the venerable Paragard, the only hormone-free IUD in the U.S. Essentially, if you're trying to make a baby, or emphatically not, CooperSurgical likely has a device or service for you. This dual focus on enabling individuals to perceive their surroundings and facilitating the very creation of new life positions CooperCompanies as a foundational, albeit sometimes overlooked, player in the grand biological narrative.

Operating globally, with CooperVision boasting a broad international footprint and CooperSurgical being more U.S.-centric, the company’s business model thrives on clinical differentiation and strategic acquisitions within these specialized medical device markets. However, even the most noble endeavors face scrutiny. Historically, the company shed non-core assets like psychiatric hospitals in a dramatic restructuring, proving that even medical device firms can have existential crises. More recently, activist investors have stirred the pot, suggesting the company should split its seemingly disparate vision and fertility businesses, arguing a lack of "synergies." Because, apparently, helping people see better and helping people reproduce are entirely unrelated cosmic functions. The company also recently navigated a significant litigation charge tied to a product recall, a stark reminder that even in the business of life, things can get messy.